Clinical Investigators Provide Perspectives on the Current and Future Management of Acute Myeloid Leukemia — Symposium Video Proceedings

Faculty

TARGET AUDIENCE
This program is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML). 

LEARNING OBJECTIVES

• Analyze patient-specific factors and available clinical trial data guiding the selection of induction therapy for primary and secondary AML to optimize clinical and quality-of-life outcomes.
• Evaluate the biological rationale for and available research findings with Bcl-2-targeted therapy for patients with AML, and appraise the current and potential role of this strategy.
• Reflect on available research evidence with approved FLT3 inhibitors, and use this information to guide the clinical care of appropriately selected patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
• Understand available efficacy and safety data with IDH1/2 inhibitors for patients with AML and an IDH1 or IDH2 mutation, and integrate these novel approaches into treatment algorithms.
• Recognize the scientific justification for the development of menin inhibitors for the treatment of certain genetically defined subsets of AML, and consider available research findings with and the current and potential role of these novel agents.
• Recall new data with agents and strategies currently under investigation for AML, and discuss ongoing trial opportunities with eligible patients.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CE ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHAML25/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Harry Paul Erba, MD, PhD
Director, Leukemia Program
Professor in the Department of Medicine
Member of the Duke Cancer Institute
Duke University School of Medicine
Durham, North Carolina

Consulting Agreements: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, GlycoMimetics Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Stemline Therapeutics Inc, Sumitomo Pharma America; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, ALX Oncology, Amgen Inc, Aptose Biosciences Inc, Ascentage Pharma, Daiichi Sankyo Inc, Forma Therapeutics, Gilead Sciences Inc, GlycoMimetics Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, Kura Oncology, MacroGenics Inc, Novartis, Oryzon, PTC Therapeutics, Sumitomo Pharma America, Taiho Oncology Inc; Speakers Bureaus: AbbVie Inc, Bristol Myers Squibb, Incyte Corporation, Jazz Pharmaceuticals Inc, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Study IRCs: AbbVie Inc (Chair, VIALE-A and VIALE-C); Study Steering Committee Chairs: Bristol Myers Squibb (AML Registry), Daiichi Sankyo Inc (QuANTUM-First and QuANTUM-Wild); Study Steering Committees: GlycoMimetics Inc, Kura Oncology, Sumitomo Pharma America; Nonrelevant Financial Relationships: Fortrea.

Amir Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Autolus, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Kura Oncology, Pfizer Inc, Prelude Therapeutics, Remix Therapeutics, Rigel Pharmaceuticals Inc, Schrödinger, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc, Thermo Fisher Scientific; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Kura Oncology, Servier Pharmaceuticals LLC.

Tara L Lin, MD, MS
Professor, Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
Kansas City, Kansas

Consulting Agreements: Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Contracted Research: Aptevo Therapeutics, Bio-Path Holdings Inc, Cardiff Oncology, CicloMed, Cleave Biosciences, Jazz Pharmaceuticals Inc, Kura Oncology, Lin BioScience; Data and Safety Monitoring Boards/Committees: Sumitomo Pharma America.

Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine
Member, Leukemia Program
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Advisory Committees: AbbVie Inc, Astellas, Daiichi Sankyo Inc, Johnson & Johnson, Rigel Pharmaceuticals Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals; Consulting Agreements: Astellas, Daiichi Sankyo Inc, Foghorn Therapeutics, Syndax Pharmaceuticals; Contracted Research: AbbVie Inc, Astellas, Daiichi Sankyo Inc, Syndax Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Foghorn Therapeutics; Nonrelevant Financial Relationships: Beat AML LLC.

Eytan M Stein, MD
Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Consulting Agreements: AbbVie Inc, Astellas, Cullinan Therapeutics, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kura Oncology, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Contracted Research: Astellas, Bristol Myers Squibb, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Stock Options — Private Companies: Auron Therapeutics.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AbbVie Inc, Astellas, Daiichi Sankyo Inc, Kura Oncology, and Rigel Pharmaceuticals Inc.

Release date: January 2026
Expiration date: January 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Lin

Geissler K et al. Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. Br J Haematol 2024;205(5):1734-45. Abstract

Pratz KW et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol 2024;99:615-24. Abstract

Venditti A et al. Fitness assessment in acute myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood Adv 2025;9(9): 2207-20. Abstract

Wei AH et al. How I treat patients with AML using azacitidine and venetoclax. Blood 2025;145(12):1237-50. Abstract

Zeidan AM et al. An all-oral regimen of decitabine-cedazuridine plus venetoclax in patients with newly diagnosed acute myeloid leukemia ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 patients. ASCO 2025;Abstract 6504.

Dr Perl

Bazarbachi A et al. Challenging the adverse label: Diverse outcomes of ELN 2022 adverse cytogenetic subgroups in acute myeloid leukemia patients allografted in first remission: From EBMT ALWP. Am J Hematol 2025;100(8):1374-86. Abstract

Daver N et al. Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed acute myeloid leukemia. ASH 2025;Abstract 651.

Daver NG et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: A phase 1/2 study. Lancet Oncol 2024;25(3):388-99. Abstract

DiNardo CD et al. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 2025;39(4):854-63. Abstract

Döhner H et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood 2024;144(21):2211-22. Abstract

Fang Q et al. Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML): A multicenter, prospective, randomized phase II trial. ASH 2025;Abstract 650.

Fathi A et al. Results from paradigm – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. ASH 2025;Abstract 6.

Lu J et al. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood 2025;145(22):2645-55. Abstract

Montesinos P et al. Quizartinib for newly diagnosed FLT3-internal tandem duplication-negative AML: The randomized, double-blind, placebo-controlled, phase II QUIWI study. J Clin Oncol 2025;[Online ahead of print]. Abstract

Dr Erba

Levis MJ et al. FLT3-ITD measurable residual disease from the QuANTUM-First trial. Blood Adv 2025;[Online ahead of print]. Abstract

Levis MJ et al. Correlation of baseline gene mutations with quizartinib efficacy in patients with FLT3-ITD-positive newly diagnosed acute myeloid leukemia in the phase 3 QuANTUM-First trial. ASH 2024;Abstract 848.

Levis MJ et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol 2024;42:1766-75. Abstract

Luger S et al. Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD Negative rate: Results of the phase 2 randomized precog 0905 study in newly diagnosed FLT3 mutated AML. ASH 2024;Abstract 221.

Montesinos P et al. Quizartinib for newly diagnosed FLT3-internal tandem duplication-negative AML: The randomized, double-blind, placebo-controlled, phase II QUIWI study. J Clin Oncol 2025;[Online ahead of print]. Abstract

Short NJ et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol 2024;42:1499-508. Abstract

Yilmaz M et al. Phase I/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML. EHA 2025;Abstract S142.

Dr Fathi

Cortes J et al. Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort. J Hematol Oncol 2025;18:102. Abstract

Cortes J et al. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: A multicohort open-label phase 1/2 trial. J Hematol Oncol 2025;18:7. Abstract

DiNardo CD et al. Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitors for intensive chemotherapy-ineligible patients with isocitrate dehydrogenase-mutated AML. J Clin Oncol 2025;43(24):2692-699. Abstract

Montesinos P et al. Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML. Blood Adv 2025;9(20):5177-89. Abstract

Watts JM et al. Looking beyond the surface: olutasidenib and ivosidenib for treatment of mIDH1 acute myeloid leukemia. Curr Treat Options Oncol 2024;25(11):1345-53. Abstract

Wei A et al. Olutasidenib as maintenance therapy after treatment response in mutated IDH1 acute myeloid leukemia. EHA 2025;Abstract PF530.

Dr Eytan Stein

Aldoss I et al. Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study. ASH 2025;Abstract 1001.

Erba H et al. Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed NPM1-M OR KMT2A-R acute myeloid leukemia (AML): Updated phase 1A/B results from KOMET-007. EHA 2025;Abstract S136.

Fathi AT et al. Ziftomenib combined with venetoclax/azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Interim phase 1a results from KOMET-007. ASH 2024;Abstract 2880.

Issa G et al. Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007. ASH 2025;Abstract 764.

Issa GC et al. Combination strategies with menin inhibitors for acute leukemia. Blood Cancer Discov 2025;6(6):547-60. Abstract

Issa GC et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol 2025;43(1):75-84. Abstract

Issa GC et al. How I treat acute myeloid leukemia with differentiation therapy. Blood 2025;145(12):1251-9. Abstract

Jen W-Y et al. Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. ASH 2025;Abstract 47.

Roboz G et al. Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007. ASH 2025;Abstract 766.

Searle E et al. Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed/refractory acute leukemia patients with KMT2A and NPM1 alteration. ASH 2024;Abstract 212.

Zeidner J et al. Azacitidine, venetoclax, and revumenib for newly diagnosed older adults with acute myeloid leukemia (AML) and NPM1 mutation or KMT2A rearrangement: Updated results from the BEATAML consortium. EHA 2025;Abstract S138.

Zeidner J et al. Phase 1B study of azacitidine, venetoclax and revumenib in newly diagnosed older adults with NPM1 mutated or KMT2A rearranged AML: Interim results of dose escalation from the BEATAML consortium. EHA 2024;Abstract S134.